Topic: marketing investigation
It seems logical: pharmas teaching doctors' staff how to handle patients using their drugs. But a slew of companies are discovering it's not so simple.
Texas spanked AstraZeneca as a repeat offender in announcing a pair of off-label marketing settlements.
After round-the-world scandals, it certainly appears Novartis has a systemic problem. But Vas Narasimhan has a clean slate—and he needs to use it.
After Michael Avenatti leveled allegations of "suspicious" payments, Novartis says it paid Michael Cohen $1.2 million for unused consulting services.
Rita Luthra, M.D., was convicted Monday in a Warner marketing scheme—and in more evidence that it's the cover-up that gets you, for lying to investigators.
A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.
Purdue made a splash with its plans to stop marketing opioids this week, but Endo, Teva, Allergan and J&J had already quit.
In other news of note, Bristol-Myers, Roche and Pfizer won new indications for key cancer drugs and Boehringer inked a marketing settlement.
Eli Lilly faces allegations it ran a "multi-tiered kickback scheme" to pump up sales of key diabetes drugs.
Confronted with an investigation into its Vivitrol marketing, Alkermes contends it’s just trying to help the U.S. get control of the opioid crisis.